Preglem
BUDAPEST, Hungary, October 7, 2010 - Richter announces the Acquisition of PregLem for an initial cash
consideration of CHF150 million (EUR114 million) and further milestone
payments of up to CHF295 million (EUR223 million).
GENEVA, August 11, 2010 - PregLem, the Swiss specialty biopharmaceutical company focused
on women's reproductive medicine, announces a world-wide, exclusive in
licensing agreement for Bentamapimod, a novel, orally active, Jun Kinase
Inhibitor (JNK-I AS602801) from Merck Serono for an undisclosed amount.
GENEVA, Switzerland, June 3, 2010 - PregLem, the European specialty biopharmaceutical company focused on
women's reproductive medicine, announces positive Phase III data from its
second pivotal study (PEARL I) for its lead product Esmya (ulipristal
acetate), as an effective treatment for uterine fibroids (myoma) - a
condition that affects millions of women worldwide.
